42 results about "Ketamine" patented technology

The invention provides a sterile, injectable pharmaceutical composition which includes a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof, a nitrite scavenger, a tonicity agent, and water, wherein the composition contains less than about 300 ppb of an N-nitrosoketamine impurity. The invention also provides a pharmaceutical product which includes a container and the composition of the invention aseptically sealed therein. The invention further provides a process for preparing the composition and product of the invention.

Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

The present disclosure provides a method for treating or ameliorating depressive symptoms in a subject, the method comprising administering to the subject a therapeutically effective amount of a composition comprising R(-)-ketamine or a pharmaceutically acceptable salt thereof.

The present invention provides (S)- or (R)-ketamine prodrugs and compositions thereof for the treatment or prevention of depression and pain. [Solution] A compound of formula (1) or a pharmaceutically acceptable salt thereof (wherein R1 is hydrogen or alkyl, and R2 is a group of formula (6)) is provided. JPEG2026123016000361.jpg3980 JPEG2026123016000362.jpg2379

Provided herein are ketamine formulations for subcutaneous injection, in particular subcutaneous formulations of ketamine useful for the treatment of various diseases and disorders. The subcutaneous ketamine preparation provided by the invention reduces stimulation and pain of an injection site.

Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.

The application belongs to the technical field of medicine, and discloses application of oxeladin in preparation of a medicine for preventing or treating perioperative hypothermia. The dose of the medicine ranges from 1 to 3 mg. The medicine is applied to perioperative hypothermia caused by general anesthesia. The general anesthesia includes sevoflurane and esketamine. The medicine further comprises a pharmaceutically acceptable carrier and / or excipient. It is found in the previous application that the incidence of hypothermia and chills after general anesthesia is significantly reduced in the oxeladin administration group compared with the blank control group, and the further verification is carried out through animal experiments. The achievement of the application provides an effective prevention and treatment scheme for improving perioperative hypothermia and chills in clinic.

The invention relates to pharmaceutical compositions comprising ketamine or pharmaceutically acceptable salt thereof for nasal administration, and methods for using such compositions.

The present invention features methods and compositions for the treatment of an emotional disorder in a subject by administering ketamine, norketamine, 6-hydroxynorketamine, or a pharmaceutically acceptable salt thereof, and cannabis or a cannabinoid in an amount that is sufficient to treat the emotional disorder.

The disclosure provides a method of treating or ameliorating depressive symptoms of a subject, comprising administering a therapeutically effective amount of a composition comprising R(−)-ketamine, or a pharmaceutically acceptable salt thereof, to the subject.

The present invention relates to a dosing regimen of 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one, also known as ketamine, or a derivative thereof for use in the treatment of depression, in particular treatment resistant depression.

The application belongs to the technical field of biological medicine, and relates to a drug for treating depression, and in particular to application of cyclopentolate combined with esketamine in preparation of a drug for treating depression. Experimental researches of the application show that, compared with cyclopentolate or esketamine alone, cyclopentolate combined with esketamine can more significantly improve the depressive behavior of CRS depressive model mice, and it is proved that cyclopentolate combined with esketamine can synergistically enhance the anti-depression effect, so as to be used as a drug for treating depression.

This invention relates to the field of pharmaceutical technology, and in particular to a cleaved C19 diterpenoid alkaloid compound and its application in rapid-acting antidepressants. This invention isolates a novel cleaved C19 diterpenoid alkaloid compound, Carmaloidline G, from Aconitum carmichaelii and establishes a stable and controllable extraction, separation, and purification process, achieving high-purity preparation and industrial-scale feasibility of this compound. Studies have shown that this compound exhibits significant rapid-acting antidepressant activity in various animal models of depression, with a fast onset of action and stable efficacy. Its overall efficacy is comparable to the positive control drug esketamine, but the required dosage is significantly reduced, thereby effectively reducing the risk of potential adverse reactions.

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and / or treatment of a depressive symptom, consisting of R(−)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and / or treatment of a depressive symptom, comprising R(−)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

The present application relates to the technical field of biological analysis detection, and particularly relates to cucurbituril derivatives for drug detection, a preparation method and application of the cucurbituril derivatives, a detection probe containing the cucurbituril derivatives, a drug for treating drug acute poisoning, and a method for drug detection. The derivative introduces a functional group of o-cyanobenzaldehyde (CNBA) on the basis of retaining the original supramolecular recognition characteristics of cucurbituril, and the obtained compound can realize efficient covalent capture on the primary amine groups in common drugs and metabolites (such as methyl phenylpropylamine and its metabolites, 3,4-methylenedioxy methyl phenylpropylamine, ketamine and its metabolites, fluoroamine and its metabolites, phenylcyclohexylpiperidine, and casiketone molecules), so as to realize rapid, high-sensitivity and visual detection on the above target objects, and can be used for antagonistic treatment of acute poisoning caused by related drugs and metabolites.

The present disclosure relates to compositions comprising racemic ketamine or a pharmaceutically acceptable salt thereof for use in the treatment of psychiatric disorders such as suicide propensity, suicide idea, major depression, anti-therapeutic depression, and post-traumatic stress disorders.

The present invention relates to an oral dosage form for administration of ketamine and a method of preparing an oral dosage form for administration of ketamine, preferably once or twice a day.

This section presents subcutaneous ketamine formulations useful for the treatment of various diseases and disorders. These formulations reduce irritation and pain at the injection site.

Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and / or treatment of a depressive symptom, consisting of R(−)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and / or treatment of a depressive symptom, comprising R(−)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+) -ketamine, and a pharmacologically acceptable salt thereof.

An aqueous composition for intranasal administration by spray including a mixture of (a) sufentanil, a salt and / or analogs thereof and (b) ketamine, a salt and analogs thereof in solution. Also, an aqueous composition for intranasal administration by spray including (a) sufentanil, a salt and / or analogs thereof in solution and an aqueous composition for intranasal administration by spray including (b) ketamine, a salt and / or analogs thereof in solution, for use in a method for the treatment or prevention of pain in a child. The composition is useful for treating or preventing pain in a child of 17 years or younger. The composition is delivered from a nasal spray device to treat or prevent the pain such as procedural pain in a child.

The invention belongs to the technical field of medicine application, and particularly discloses application of esketamine in treating teenager depressive disorder with suicide risk and refractory, so as to play a quick anti-depression effect on teenager patients, obviously reduce the suicide risk of the patients, and have the advantages of less adverse reaction, high bioavailability and no toxic or side effect. An important feasible treatment means is provided for teenager patients, and the compound has a great application prospect as a novel anti-depression drug.

To provide an effective, long-term and safe pharmaceutical composition for use in a method of treating treatment-refractory or treatment-resistant depression in a patient diagnosed as having the depression.SOLUTION: A pharmaceutical composition for use in a method of treating treatment-resistant depression in a patient, wherein the pharmaceutical composition comprises esketamine and wherein the patient has not responded to at least two oral antidepressants in a current depressive episode, the pharmaceutical composition comprising: The method provides a pharmaceutical composition comprising: administering esketamine to the patient at least twice a week during a first induction phase of at least 4 weeks; evaluating the patient during the first induction phase; wherein the patient does not achieve a substantially complete response to esketamine; and re-starting the patient with the highest tolerated dose of esketamine in a second induction phase of at least 4 weeks.SELECTED DRAWING: None

The invention provides a construction method and application of a KIF5C gene knockout animal model, and relates to the technical field of biological medicines. The sgRNA for knocking out the KIF5C gene is characterized in that the sequence of the sgRNA is selected from at least one of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 4. The invention further discloses a preparation method of the sgRNA for knocking out the KIF5C gene. The KIF5C gene knockout animal model disclosed by the invention can be used as an animal model for depression and disease research, the KIF5C gene knockout animal model is prepared by adopting a gene knockout technology, and animal behavioral detection shows that a mouse has depression-like symptoms (a sweet water preference experiment and a forced swimming experiment) and memory dysfunction (a Y maze experiment and a conditional fear experiment); the compound has depression symptoms, can be reversed through an antidepressant drug ketamine, and can be used for researching depression animal models and developing corresponding drugs.

The invention provides application of esketamine in preparation of hyperalgesia drugs, and relates to the technical field of clinical medicine. Clinical tests and animal experiments are combined, it is systematically proved that sub-anesthetic dose esketamine can effectively relieve diabetic hyperalgesia, and a novel molecular action mechanism of esketamine is disclosed. Preliminary tests and animal experiments show that the scheme can significantly improve the mechanical pain threshold and reduce the pain score, and the effect is exact. In mechanism, it is clarified for the first time that esketamine regulates and controls downstream PI3K / Akt / GSK-3beta signal channels by inhibiting excessive activation of an NMDA receptor, and abnormal expression and membrane transport of a GLuR1 receptor are reduced, so that central sensitization is reversed. The scheme has the advantages of quick response, no opioid drug dependence, clear mechanism and the like, provides a new safe, effective and clear-target analgesic strategy for clinical treatment of diabetes-related neuropathic pain, and has good transformation and application prospects.

Provided are prodrugs of (S) -or (R) -ketamine, including isotopically labeled ketamine,composition and uses thereof. Compounds having formula (Ia) or (Ib) as the prodrugs of (S) -or (R) -ketamine, including isotopically labeled ketamine, and pharmaceutical compositions comprising the compounds provided herein are used for treating or preventing a CNS disease.More particularly, the related diseases include depression and pain. (Ia) (Ib)

The present invention provides a topical formulation comprising active ingredient(s) lidocaine, ketamine, or pharmaceutically acceptable salt thereof for dermal application and method of use to treat or relieve pain. The topical formulation comprises active pharmaceutical agents lidocaine, ketamine, or their pharmaceutical salt thereof; one or more skin penetration enhancers; and a drug delivery matrix system. The topical formulations are aimed at relieving pain including any type of pain in body, joint pain, chronic pain states such as post-herpetic neuralgia, complex regional pain syndrome, and arthritis. The topical formulation dries and forms a clear film on the skin and as it comprises water insoluble excipients, it is reasonably wash resistant.

The invention provides a sterile, injectable pharmaceutical composition which includes a therapeutically effective amount of ketamine or a pharmaceutically acceptable salt thereof, a nitrite scavenger, a tonicity agent, and water, wherein the composition contains less than about 300 ppb of an N-nitrosoketamine impurity. The invention also provides a pharmaceutical product which includes a container and the composition of the invention aseptically sealed therein. The invention further provides a process for preparing the composition and product of the invention.